Actavis: A Generic Rival Agreed to Promote the Brand

The Actavis AndroGel reverse payment case challenged a deal under which Solvay promised Actavis an estimated $19 to $30 million annually while Actavis agreed to delay its generic launch and promote AndroGel. Actavis Inc., then known as Watson Pharmaceuticals, had obtained Food and Drug Administration approval for its competing product. The Federal Trade Commission alleged that the brand manufacturer was paying its challengers to stay out of the market. The company positioned to bring a cheaper alternative to doctors had agreed to help promote the brand instead.

On June 17, 2013, the Supreme Court overturned the dismissal of the Federal Trade Commission’s challenge. The decision opened the agreement to examination under antitrust law. Solvay’s patent alone could no longer shield the payment from that examination.

How the Generic Challenge Worked

Actavis was the first generic applicant challenging the patent behind AndroGel. That position carried a commercial advantage: a chance to sell its generic before other generic manufacturers could enter. The first challenger had something valuable both to pursue and to give up.

Solvay obtained Food and Drug Administration approval for AndroGel in 2000 and a relevant patent in 2003. Later that year, Watson applied to market a generic version. Paddock Laboratories submitted a separate application. Par Pharmaceutical joined Paddock’s effort, sharing the patent-litigation costs in return for a share of the profits if Paddock won approval.

The Supreme Court’s explanation of the approval process shows why the patent challenge mattered. A generic manufacturer can rely on the brand’s earlier approval work, showing that its product has the same active ingredients and is biologically equivalent. It can avoid repeating the brand’s full development studies while seeking permission to compete.

A paragraph IV challenge asserts that the listed patent is invalid or that the generic product would not infringe it. Actavis and Paddock made both assertions about Solvay’s patent. Solvay sued them. A timely patent suit usually holds approval for roughly 30 months while the dispute proceeds. Here, the Food and Drug Administration eventually approved Actavis’s first-filed product. The approval obstacle had been cleared when the companies chose their settlement.

What the AndroGel Agreement Bought

The 2006 patent settlement tied a delayed generic launch to payments and promotional work. Actavis agreed to keep its generic off the market until August 31, 2015, unless another company marketed a generic sooner. The date was 65 months before Solvay’s patent expired.

Actavis also agreed to promote AndroGel to urologists. The other generic manufacturers made roughly similar promises. According to the Court’s account of the agreement, Solvay’s annual payments to Actavis were to run for nine years. Solvay also agreed to pay Paddock $12 million in total and Par $60 million in total.

The companies described the money as compensation for services. The Federal Trade Commission alleged that those services had little value and that the real purpose was to compensate the generic manufacturers for delaying competition. The dispute therefore reached inside the commercial arrangement: what work was promised, what that work was worth, and why the brand was paying a potential competitor to perform it.

That is why this is called a reverse payment. Solvay had sued the generic companies over its patent, yet the money was to flow from Solvay to the companies it had sued. In the FTC’s account, the payment bought relief from the competition those companies had been preparing to offer.

Why Paying the First Challenger Matters

A payment to the first challenger can remove the generic manufacturer best placed to compete quickly. The Court explained that the approval system gave later challengers less to gain and their own regulatory wait to overcome.

The first applicant could earn 180 days of generic exclusivity once it began commercial marketing. Later applicants could not claim that same first-filer advantage. A successful later patent challenge could open the market to other approved competitors too, leaving the later challenger to share the benefit of its work.

This helps explain why paying the initial challengers could preserve the brand’s position. Another manufacturer would have to undertake its own challenge with less to gain from winning. If the brand sued, that manufacturer would also face an approval hold. The Court treated those incentives as central to the agreement’s potential effect on competition.

For the brand and its challenger, sharing the return from continued high prices could be more attractive than competing for sales at lower prices. The customer buying the medicine had no share of that bargain. The majority put the conflict plainly:

What the Supreme Court Changed

The Supreme Court required an examination of what the payment bought and how it affected competition. The majority identified the comparisons that mattered: the size of the payment, its scale against the patent holder’s expected litigation costs, whether it paid for other services, and any other convincing explanation. A large payment unexplained by those considerations could indicate that the brand was buying protection from competition.

The size of an unexplained payment could reveal the value the brand placed on avoiding competition. Even a patent holder confident in its patent might pay to remove that risk. The question was what the payment was buying.

The distinction has practical force for someone inside a manufacturer. A contract can describe a service, while the amount paid reflects something else. In this case, the Federal Trade Commission challenged the value of the promised services directly. Comparing the service’s commercial value with the payment was part of the inquiry the lower courts had shut down.

The Work Behind the Promotion Fee

The AndroGel service explanation makes the people who understood the promotion arrangement especially relevant. The companies said they were paying for services, and the Federal Trade Commission alleged that those services had little value. Someone who knew the promised work could help explain the gap between those accounts.

We examine the agreement alongside the work it called for, the payment records and the decisions about launching the competing product. For a promotion arrangement, that means understanding what the generic company agreed to deliver and what the brand expected to receive. It also means connecting the service fee to the agreement that set the generic’s entry date.

The Court specifically recognized avoided litigation costs and fair value for services as explanations to examine. An insider’s knowledge of the commercial work can make that comparison concrete. A fee description alone leaves unanswered why the brand chose that company, that amount and that accompanying restriction on entry.

Pay-for-Delay Agreements After the Ruling

Potential pay-for-delay deals fell from 40 in fiscal 2012 to 14 in fiscal 2015, according to Public Citizen’s 2018 report, Twenty-Seven Years of Pharmaceutical Industry Criminal and Civil Penalties: 1991 Through 2017. The report drew on the Federal Trade Commission’s settlement reports, placing that decline after the Supreme Court’s ruling.

The pattern concerned agreements that paired compensation with restrictions on generic entry. For this case, the terms remain especially concrete: a generic launch date, payments to the challengers and work promoting the brand.

Actavis Inc. Versus Actavis PLC: Two Different Antitrust Cases

The Actavis Inc. and Actavis PLC antitrust cases concern different conduct. Actavis Inc., formerly Watson Pharmaceuticals, was the generic challenger in the AndroGel reverse-payment dispute. In the separate Actavis PLC product-switching case, the court addressed product withdrawal combined with conduct that coerces consumers and impedes competition.

Watson’s separate average wholesale price litigation concerned reported drug prices. Across pharmaceutical cases, the transaction explains which story an insider recognizes.

If you know how a service arrangement connects to claims submitted for government payment, our pharmaceutical whistleblower experts can assess that connection with you. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What the Agreement Bought

If you know how a generic launch became a paid service arrangement, your knowledge of what the fee really bought is where we start. Our whistleblower experts work alongside you to build your strongest pharmaceutical whistleblower case and bring in pharmaceutical whistleblower lawyers who understand competition disputes and government-payment claims. Talk with us about the deal you know from the inside.